Literature DB >> 7966646

Lymphocytic choriomeningitis virus-induced immune dysfunction: induction of and recovery from T-cell anergy in acutely infected mice.

E A Butz1, P J Southern.   

Abstract

Acute infection of immunocompetent mice by lymphocytic choriomeningitis virus induces a potent cytotoxic T-lymphocyte response that eliminates infectious virus. Concurrently and paradoxically, there is a general suppression of lymphocyte responses to mitogens and to other infectious agents. Splenocytes from infected mice released significant amounts of gamma interferon in response to mitogenic stimulation in vitro, but neither interleukin 2 nor interleukin 4 was similarly elevated relative to the amounts released by control cells. Early T-cell receptor-proximal signaling events were found to be intact, confirming that the cells were viable and had received the mitogenic stimuli in an appropriate manner. Acutely infected adult thymectomized mice regained concanavalin A responsiveness in parallel with euthymic mice, if T cells were left unmanipulated for several weeks after clearance of virus from the mice. Therefore, although acute lymphocytic choriomeningitis virus infection has the effect of disrupting proliferation when the T-cell receptor is ligated, this state is only temporary. In contrast, T cells from persistently infected adult mice reveal long-lasting alterations in concanavalin A responsiveness.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7966646      PMCID: PMC237326          DOI: 10.1128/JVI.68.12.8477-8480.1994

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  32 in total

1.  The activation of IL-2 transcription in L3T4+ and Lyt-2+ lymphocytes during virus infection in vivo.

Authors:  M T Kasaian; C A Biron
Journal:  J Immunol       Date:  1989-02-15       Impact factor: 5.422

2.  Virus-lymphocyte interactions. II. Expression of viral sequences during the course of persistent lymphocytic choriomeningitis virus infection and their localization to the L3T4 lymphocyte subset.

Authors:  A Tishon; P J Southern; M B Oldstone
Journal:  J Immunol       Date:  1988-02-15       Impact factor: 5.422

3.  Generation of large granular T lymphocytes in vivo during viral infection.

Authors:  C A Biron; R J Natuk; R M Welsh
Journal:  J Immunol       Date:  1986-03-15       Impact factor: 5.422

4.  Effective clearance of a persistent viral infection requires cooperation between virus-specific Lyt2+ T cells and nonspecific bone marrow-derived cells.

Authors:  B D Jamieson; L D Butler; R Ahmed
Journal:  J Virol       Date:  1987-12       Impact factor: 5.103

5.  Virus-lymphocyte interaction: T cells of the helper subset are infected with lymphocytic choriomeningitis virus during persistent infection in vivo.

Authors:  R Ahmed; C C King; M B Oldstone
Journal:  J Virol       Date:  1987-05       Impact factor: 5.103

Review 6.  The virology and immunobiology of lymphocytic choriomeningitis virus infection.

Authors:  M J Buchmeier; R M Welsh; F J Dutko; M B Oldstone
Journal:  Adv Immunol       Date:  1980       Impact factor: 3.543

7.  Lymphocytic choriomeningitis virus-induced immunosuppression: a virus-induced macrophage defect.

Authors:  R P Jacobs; G A Cole
Journal:  J Immunol       Date:  1976-09       Impact factor: 5.422

8.  Age-dependent susceptibility of murine T lymphocytes to lymphocytic choriomeningitis virus.

Authors:  F Lehmann-Grube; R Tijerina; W Zeller; U C Chaturvedi; J Löhler
Journal:  J Gen Virol       Date:  1983-05       Impact factor: 3.891

9.  Transient impaired cell-mediated tumor immunity after acute infection with lymphocytic choriomeningitis virus.

Authors:  F Güttler; K Bro-Jorgensen; P N Jorgensen
Journal:  Scand J Immunol       Date:  1975       Impact factor: 3.487

10.  Immunopathologic alterations of lymphatic tissues of mice infected with lymphocytic choriomeningitis virus. I. Histopathologic findings.

Authors:  J Löhler; F Lehmann-Grube
Journal:  Lab Invest       Date:  1981-03       Impact factor: 5.662

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.